The therapeutic pre- and postsynaptic benefits of β-adrenoceptor agonists (salbutamol and ephedrine) have been reported in MuSK MG animal models [101], neonatal myasthenia gravis (FARIS, caused by fetal AChR γ-subunit antibodies [72,73]) [102] and MG patients with nAChR antibodies [103] as well as various types of congenital myasthenic syndrome [104,105] including the patients suffering from mutations in MuSK [106] and Lrp4 [107]. The gene discussed is CHRNA4; the disease is myasthenia gravis.